p38γ Promotes Breast Cancer Cell Motility and Metastasis through Regulation of RhoC GTPase, Cytoskeletal Architecture, and a Novel Leading Edge Behavior

Devin T. Rosenthal1,4, Harish Iyer2, Silvia Escudero6, Liwei Bao3, Zhifen Wu1, Alejandra C. Ventura7, Celina G. Kleer3,4,5, Ellen M. Arruda2, Krishna Garikipati2, and Sofia D. Merajver1,4,5

Abstract
Understanding the molecular alterations that confer cancer cells with motile, metastatic properties is needed to improve patient survival. Here, we report that p38γ mitogen-activated protein kinase regulates breast cancer cell motility and metastasis, in part, by controlling expression of the metastasis-associated small GTPase RhoC. This p38γ–RhoC regulatory connection was mediated by a novel mechanism of modulating RhoC ubiquitination. This relationship persisted across multiple cell lines and in clinical breast cancer specimens. Using a computational mechanical model based on the finite element method, we showed that p38γ-mediated cytoskeletal changes are sufficient to control cell motility. This model predicted novel dynamics of leading edge actin protrusions, which were experimentally verified and established to be closely related to cell shape and cytoskeletal morphology. Clinical relevance was supported by evidence that elevated expression of p38γ is associated with lower overall survival of patients with breast cancer. Taken together, our results offer a detailed characterization of how p38γ contributes to breast cancer progression. Herein we present a new mechanics-based analysis of cell motility, and report on the discovery of a leading edge behavior in motile cells to accommodate modified cytoskeletal architecture. In summary, these findings not only identify a novel mechanism for regulating RhoC expression but also advance p38γ as a candidate therapeutic target.

Cancer Res; 71(20); 6338–49. ©2011 AACR.

Introduction
Breast cancer presents as a dysplastic disease of mammary epithelial cells, which can grow uncontrollably for years yet remain confined within mammary ducts or lobules. If diagnosed at an early stage, breast cancer responds well to therapeutic intervention (1). Breast cancer becomes much more severe once the cancer cells exit the mammary ducts and metastasize to vital organs. Understanding the molecular alterations that confer metastatic properties to otherwise benign cells is therefore essential in controlling the disease and improving patient survival.

p38 mitogen-activated protein kinase (MAPK) is a serine/threonine kinase that integrates extracellular stimuli and translates them into cellular responses by phosphorylating a network of downstream effector proteins (2). The p38 arm of...
Quick Guide to Main Model Equations and Major Assumptions of the Model

The partial differential equation that governs the quasistatic balance of linear momentum of the cell is more amenable to computational solution when it is written in weak form:

Find $u$ such that for all $w$,

$$
\int \nabla^S w : \sigma[u] \, dV = 0,
$$

in which $u$ is the displacement field vector, $w$ is the weighting function vector, and $\sigma[u]$ is the stress tensor, here written to emphasize its dependence on the displacement field via the strain tensor $\varepsilon[u]$. The symbol $\nabla^S$ denotes the symmetric part of the gradient operator.

Major assumptions for equation A

At the typical speeds of cell motility, the effect of inertia is negligible, and the "dynamic" balance of linear momentum need not be considered.

The strain tensor is defined as

$$
\varepsilon(u) = \nabla^S u.
$$

Major assumptions for equation B

The infinitesimal strain theory is assumed to hold, according to which nonlinear dependence of $\varepsilon$ upon $u$ can be neglected. This assumption makes for a simpler mathematical formulation and more rapid computations. The fully nonlinear theory leads to some quantitative differences in the computed stress but does not alter the results in a qualitative manner.

The stress–strain response of the actin fibers and cell membrane is governed by the constitutive equation:

$$
\sigma = \lambda/\text{tr}(\varepsilon) + 2\mu\varepsilon,
$$

in which $\lambda$ and $\mu$ are Lamé parameters defined in terms of the more familiar Young’s Modulus $E$ and Poisson ratio $v$ by

$$
\lambda = \frac{vE}{[(1 + v)(1 - 2v)]} \quad \text{and} \quad \mu = \frac{E(1 + v)}{2(1 + v)}
$$

Major assumptions for equation C

The actin fibers and cell membrane are assumed to be elastic. This assumption implies that viscous effects associated with the kinetics of binding/unbinding of actin monomers with the cytoskeletal fibers and the lipid bilayer will not be accounted for in the stress computations. We note, however, that the purpose of the computational model in this work is to represent the kinematics of cell motility and locomotion, and not to provide a precise computation of the stress. With more appropriate viscoelastic models for the actin fibers and cell membrane, the stress computed is more physically accurate, but the fundamental conclusions reached on cell motility and locomotion do not change. The viscoelastic models also result in a more complicated mathematical formulation and slightly slower computations.

The matrix–vector version of the weak form (A) is

$$
K\ddot{d} = F
$$

in which $K$ is the finite element stiffness matrix, which includes the influence of the mechanical properties, $\ddot{d}$ is the vector of nodal displacements, and $F$ is the external force vector. The latter includes the effect of displacement boundary conditions that model the attachment of the cell to the substrate at focal adhesions.

Major assumptions for equation D

Our finite element implementation is based on the plane stress model of mechanics. Plane stress is an appropriate model for the 2-dimensional shape adopted by cells on a substrate.
Viewing p38γ function from the developmental perspective led us to hypothesize that p38γ enables mesenchymal-like behavior in breast cancer cells by controlling their motility properties.

Using multiple mechanisms of inhibition, we reveal that p38γ is a crucial mediator of breast cancer cell motility and metastasis. Our computational model shows the central role of stress fiber orientation in p38γ-mediated cell motility. Through this in silico experimentation, and subsequent in vitro validation, we discovered a novel leading edge behavior in motile breast cancer cells. Mechanistically, p38γ elicits its effects at least in part through RhoC GTPase by affecting RhoC ubiquitination and degradation—a regulatory mechanism never before observed for RhoC. Clinically, high p38γ expression is associated with the basal-like breast cancer subtype and confers a worse prognosis. This work establishes that p38γ is a metastasis-enabling gene responsible for mediating breast cancer cell motility and metastasis, in part, by regulating cytoskeletal architecture and modulating RhoC.

Materials and Methods

Cell lines

Untransfected cell lines were cultured in RPMI-1640 (MDA-MB-231, BT549) or Dulbecco’s Modified Eagle’s Medium (DMEM; Hs578t) supplemented with 10% FBS or DMEM/Ham’s F-2 (MCF-10A) supplemented with 10% horse serum. Selection media for short hairpin RNA (shRNA)-transfected MDA-MB-231 cells (“scrambled” or “shp38γ”) was standard cell line media containing 1 μg/mL puromycin. MDA-MB-231 stably transfected with both shRNA and RhoC/RhoC G14V were cultured in standard cell line media containing 1 μg/mL puromycin and 350 μg/mL G418. All cell lines were grown at 37°C in a humidified 5% CO₂ incubator.

Phospho-p38γ immunoprecipitation/Western blotting

Protein was extracted from 70% confluent cells with radioimmunoprecipitation assay buffer. Total protein extracts were incubated with primary antibody (anti-p38γ or anti-phospho-p38) overnight at 4°C. The following morning protein–antibody complexes were captured by incubation with protein A/G beads (Santa Cruz Biotechnology). Immunoprecipitates were run on an SDS-PAGE gel, transferred to a nitrocellulose membrane, and probed with the appropriate reciprocal antibody (anti-p38γ or anti-phospho-p38). All immunoprecipitation and Western blot data represent at least 3 independent experiments.

In situ detection/quantification of protein expression

Tumors and patients. Resh and formalin-fixed, paraffin-embedded tissue blocks of breast cancer were obtained from the files of the Department of Pathology, University of Michigan Medical Center (Ann Arbor, MI). Institutional Review Board approval was obtained, and the diagnosis was confirmed by morphology. After pathologic review, a tissue microarray was constructed from the most representative area by the methodology of Nocito and colleagues (16). Survival data were obtained from the University of Michigan’s Cancer Registry.

Immunohistochemical staining and AQUA analysis.

Triple immunofluorescence staining was carried out as previously described (17), and the AQUA system (HistoRx) was used for automated image acquisition and analysis. See Supplementary Materials and Methods for the detailed staining and imaging procedure.

Orthotopic xenografts and lymphatic metastasis analysis

All mouse work was compliant with the University’s standards for animal use. A total of 231 scrambled and shp38γ cells were diluted at a ratio of 1:1 with Matrigel (BD Biosciences) to a final concentration of 3 × 10⁶ cells per mL. Athymic nude mice were anesthetized, and 1.5 × 10⁵ cells (50 μL) were injected directly into the fourth mammary gland. Tumors were monitored weekly, and mice were euthanized once tumor volume approached 2 cm³. Tumors were resected at euthanization, fixed in 10% formalin, and subsequently paraffin embedded. Hematoxylin and eosin-stained tumor sections were scored for lymphatic metastasis in a single-blind manner by Dr. J. Erby Wilkinson at the ULAM Pathology Core at the University of Michigan. Lymphatic metastasis was defined as the presence of tumor cells in the inguinal lymph node of the uninjected fourth mammary gland (the contralateral gland, relative to injection site), thus indicating the ability of tumor cells to exit the primary tumor and metastasize to distant sites through the vasculature. The number of mice presenting with lymphatic metastases was compared by the Fisher exact test. Images were captured at room temperature, using an Olympus BX-51 upright light microscope with Olympus UPlanApo ×10/0.4 numerical aperture and ×40/0.85 numerical aperture objectives and an Olympus DP-70 high-resolution digital camera with DP controller software.

Statistical analyses

All data are representative of at least 3 independent experiments, and all error bars are mean ± SEM unless otherwise indicated. All P values were calculated by the Student 2-tailed t test unless otherwise noted. Expression levels of p38γ and RhoC in tissue microarray samples were compared using Spearman rank correlation coefficient. Associations between p38γ and breast cancer subtype and the prevalence of lymphatic metastasis between scrambled and shp38γ cells were determined by the Fisher exact test. The relationship between p38γ expression and patient survival was calculated by Kaplan–Meier analysis, with surviving patients censored. The log-rank test statistic was used for significance.

Results

p38γ phosphorylation is elevated in an aggressive breast cancer cell line

p38 is activated by dual phosphorylation of the threonine and tyrosine residues of the conserved TGY motif (3, 18). To assess p38γ functional relevance in aggressive breast cancer, we assayed phospho-p38γ levels in a representative and widely used aggressive breast cancer cell line, MDA-MB-231 (‘231
cells). Compared with the nontumorigenic mammary epithelial cell line MCF-10A, MDA-MB-231 cells have increased levels of phosphorylated p38\(^\text{g}\), despite similar levels of total p38\(^\text{g}\) (Fig. 1A).

To investigate the role of p38\(^\text{g}\) on the metastatic features of MDA-MB-231 cells, we used shRNA to stably knock down p38\(^\text{g}\) expression (Fig. 1B). Importantly, the shRNA did not affect expression of the other 3 p38 isoforms (Supplementary Fig. S1A). Because there is no p38\(^\text{g}\)-specific pharmacologic inhibitor, we overexpressed dominant-negative p38\(^\text{g}\) (DNp38\(^\text{g}\); ref. 19) in MDA-MB-231 cells as an additional inhibition method (See Supplementary Materials and Methods).

p38\(^\text{g}\) knockdown alters cell shape and cytoskeletal architecture

Immediately apparent in the p38\(^\text{g}\) knockdown cells (shp38\(^\text{g}\) cells) was an altered cell morphology compared with scrambled control cells (scrambled cells). Although scrambled cells exhibited the elongated morphology characteristic of MDA-MB-231 cells and mesenchymal cells in general, shp38\(^\text{g}\) cells adopted a more rounded shape (Fig. 1C), as did DNp38\(^\text{g}\) cells (Supplementary Fig. S2C). This change was quantified by the aspect ratio of cells (see Supplementary Materials and Methods). As depicted in Fig. 1C (right), shp38\(^\text{g}\) cells are significantly less elongated than scrambled cells.

We further asked whether the actin cytoskeleton was modified in shp38\(^\text{g}\) cells. Immunofluorescent confocal microscopy revealed that shp38\(^\text{g}\) cells have a strikingly disorganized actin cytoskeleton (Fig. 1D), as do DNp38\(^\text{g}\) cells (Supplementary Fig. S2E). Scrambled cells exhibit mesenchymal-like polarization with cell-length stress fibers oriented at 3.42 ± 3.9 degrees (mean ± SD) on either side of the normal to the leading edge (Fig. 1D). shp38\(^\text{g}\) cells retain thick actin bundles resembling stress fibers but primarily confined to the leading edge and with a bimodal orientation distribution at 61.08 ± 3.94 degrees (mean ± SD; Fig. 1D). This cluster of actin bundles forms the lamellipodia-like structure present in...
shp38γ cells (Fig. 1C and D) but shows little similarity to classic lamellipodial cytoskeletal architecture, which normally consists of thin, branched actin filaments forming a protrusive meshwork (20).

**p38γ knockdown dramatically alters cell motility and affects other in vitro metastasis-associated properties of MDA-MB-231 cells**

Elongated cell shape is one factor that delineates both the mode of motility used by a cell and metastatic from non-metastatic cancer cells in vitro (21, 22). To determine whether the rounded shape and modified cytoskeletal architecture of shp38γ cells indicated a change in metastatic properties, we first analyzed cell motility—specifically unstimulated random walk—by time-lapse microscopy.

p38γ knockdown profoundly affected the quality of cell motility (Fig. 1E, left) and their speed (Fig. 1E, right). Scrambled control cells had a mesenchymal-like motility, consistent with their appearance and cytoskeletal structure, using long pseudopodial projections to "pull" themselves along in alternating cycles of protrusion and contraction (Fig. 1E, top left, and Supplementary Movie S1). shp38γ cells, however, remained unpolarized and were unable to form long pseudopodia (Fig. 1E, bottom left, and Supplementary Movie S2). The cells moved inefficiently using broad lamellipodia-like structures and exhibited detachment anomalies at the rear of the cell. Quantitatively, p38γ knockdown significantly reduced cell speed (Fig. 1E, right).

We also investigated p38γ function in cancer cell invasion and aggressive 3-dimensional growth and found that p38γ knockdown significantly impaired both properties (Supplementary Fig. S1B and S1C). These data show that p38γ knockdown affects the in vitro metastasis-related properties of aggressive breast cancer cells and specifically inhibits efficient mesenchymal-like motion in a qualitative and quantitative manner.

**Computational modeling reveals that p38γ-induced changes in cytoskeletal architecture influence cell motility**

We observed that p38γ knockdown had functional (impaired motility and other metastasis-related properties) and structural (actin cytoskeleton and cell shape) effects on MDA-MB-231 cells. However, there remained the question of whether the change in actin cytoskeletal structure is sufficient to explain the observed impairment of motility. Because it remains inaccessible to experiments, this central question was addressed by computational modeling.

Our computational models use the finite element method to solve the partial differential equations governing the mechanics of cell motility (see Supplementary Materials and Methods for details). We hypothesized that the strikingly different cytoskeletal architectures—polarized stress fibers in scrambled versus bimodal bundles of fibers in shp38γ cells—underlie the observed differences in motility.

To test this hypothesis, we first created a computational model of scrambled cell motility. Using the typical dimensions of scrambled cells (Supplementary Table S2; Fig. 1C), their observed cytoskeletal morphology of ±3.42 degrees (Fig. 1D), and the mechanical properties of actin fibers and cell membranes of mammalian cells (Supplementary Table S1), we varied the rates of actin filament protrusion and retraction as model inputs to successfully recreate the observed locomotion of live scrambled cells (Fig. 1F, top, and Supplementary Movie S3).

To determine whether actin cytoskeletal architecture delineates the motility of the 2 MDA-MB-231 phenotypes, we next created a computational model of shp38γ cells, using the dimensions reported in Supplementary Table S2 and Fig. 1C, the cytoskeletal morphology of actin bundles at ±61.08 degrees (Fig. 1D and Supplementary Fig. S3), and the same mechanical properties of actin fibers and cell membrane as for the scrambled cells (Supplementary Table S1). We further conjectured, and computationally showed, that the observed oscillations in motion of shp38γ cells that are evident in Supplementary Movie S2 were only possible if the 2 families of actin bundles at ±61.08 degrees alternate (are out of phase) in their protrusion/retraction (data not shown). When incorporated, these alternating dynamics, albeit not precisely timed, produced a disjoint crawling motion with oscillations of the cell body of the computational shp38γ cell. This motility was remarkably similar to our live shp38γ cell motility (Fig. 1E, bottom, and Supplementary Movie S3), suggesting that actin cytoskeletal architecture is important for defining shp38γ cell motility. However, further experiments were necessary to separate the influence of actin fiber orientation from actin protrusion/retraction dynamics.

**Live scrambled and shp38γ cells have oscillating leading edge protrusions related to modified cytoskeletal architecture**

The computational shp38γ cell motility thus revealed the possibility of a previously unobserved aspect of cellular dynamics, namely, waves of oscillating left- and right-of-center protrusion at the leading edge of a migrating cell. To test this model prediction, we studied in detail the dynamic behavior of the leading edge of scrambled and shp38γ cells stably transfected with red fluorescent protein (RFP)-actin.

Using time-lapse microscopy and image edge detection techniques (Supplementary Materials and Methods), we observed remarkable differences in leading edge protrusion between scrambled and shp38γ cells (Fig. 2A and C). At first observation, scrambled cells appeared to protrude in a continuous motion whereas shp38γ cells had alternating left- and right-of-center protrusions, corresponding to the 2 families of actin bundles at ±61.08 degrees (Fig. 2A). Upon closer analysis, leading edge protrusion in both cell lines actually manifested alternations between left- and right-of-center leading edge regions (Fig. 2B and C). (In the case of scrambled cells, these regions correspond to the stress fibers at ±3.42 degrees.) However, the cell lines were distinguished by the time half-period between left and right protrusions being much longer (4.83 ± 1.09 minutes) in shp38γ cells than in scrambled cells (1.75 ± 0.14 minutes; Fig. 2D). This periodicity is evident in the time-lapse movies as the disjoint crawling motion of shp38γ cells (Supplementary Movie S2),
contrasting with the coordinated protrusion/retraction cycle of scrambled cells (Supplementary Movie S1). Also note the larger amplitudes of leading edge protrusions in shp38γ cells (Fig. 2C).

These live cell results confirmed the computational model predictions. We repeated our computational cell motility studies with the mean left/right leading edge protrusion amplitudes and time periods, and trailing edge retraction rates (Supplementary Fig. S4A), which we measured via time-lapse microscopy, now used as targets to be met by controlling the actin fiber extension/contraction rates in the model (Supplementary Materials and Methods). Incorporating these experimentally measured dynamics further refined our computational models, showed good agreement between the live and computational cells, and importantly did not fundamentally alter the refined computational cell model results from the initial ones in a qualitative sense (compare Figs. 1F and 2E; Supplementary Movie S4). Through a series of additional control computational simulations (Supplementary Fig. S4 and Supplementary Results), we determined that, other parameters remaining the same, modifications in cytoskeletal architecture alone are sufficient to influence cell motility in the manner observed experimentally—from creating effective locomotion in live scrambled cells to ineffective locomotion of shp38γ cells.

Expression of the cytoskeletal remodeler and metastasis-promoting gene RhoC is decreased in shp38γ cells

Rho-family GTPases (Rac, Rho, and cdc42) are the classic regulators of actin cytoskeletal dynamics driving cell motility (23). On the basis of the actin cytoskeletal changes and motility defects we observed, we hypothesized that p38γ
knockdown affected the members of the Rho GTPase family. Interestingly, we found that RhoC GTPase protein levels were downregulated in both shp38γ and DNp38γ cells (Fig. 3A and Supplementary Fig. S2F), with no change in the close homolog RhoA (data not shown). Surprisingly, RhoC mRNA levels were unaffected by p38γ knockdown (Fig. 3B), suggesting that p38γ influences RhoC expression at the translational or posttranslational level.

p38γ knockdown leads to increased RhoC ubiquitination and degradation

To determine whether p38γ affects RhoC expression at the translational or posttranslational level, we treated scrambled and shp38γ cells with the translation inhibitor cycloheximide and observed the effect on protein expression. Cycloheximide treatment caused RhoC protein levels to rapidly decrease in shp38γ cells, with no corresponding decrease in scrambled cells (Fig. 3C), indicating that RhoC protein is less stable in shp38γ cells.

Upon observing this change in stability, we asked whether RhoC was ubiquitinated in shp38γ cells—a common marker of proteins slated for degradation. Upon assaying RhoC ubiquitination, we found that levels of ubiquitinated RhoC were increased in shp38γ compared with scrambled cells (Fig. 3D).

To elucidate the RhoC degradation mechanism, we treated cells with either proteasome inhibitors (MG132 or lactacystin) or lysosome inhibitors (ammonium chloride or chloroquine) and observed the effect on RhoC protein levels. Lysosome inhibition caused an increase in RhoC protein (Fig. 3E), whereas proteasome inhibitors had no effect on RhoC expression (Supplementary Fig. S1D), indicating that ubiquitinated RhoC is degraded by the lysosome. Taken together, these data support the conclusion that p38γ affects RhoC expression by
mediating RhoC protein stability through regulation of RhoC ubiquitination and lysosomal degradation.

Rescuing RhoC expression restores motility to shp38γ cells

On the basis of the established roles of RhoC in cell motility and metastasis (24, 25), we hypothesized that decreased RhoC expression in shp38γ cells directly contributes to the impaired motility of shp38γ cells. To test this hypothesis, we stably transfected either RhoC or a constitutively active variant (RhoC G14V) into shp38γ cells and observed the effect on cell motility (Fig. 3F).

Live cell microscopy revealed that reexpressing RhoC significantly increased motility of the shp38γ cells to levels comparable with scrambled control cells (Fig. 3G). Interestingly, the cell speed increase seemed to have a near-linear relationship with RhoC expression/activity. Combined with our previous observations, these data establish a novel mechanistic link whereby p38γ directs cell motility through stabilization of RhoC protein.

p38γ and RhoC expression is strongly positively correlated in human breast cancer tissues

We next asked whether the p38γ–RhoC relationship persists in human breast cancer tissues. To address this question we assayed expression of p38γ and RhoC using AQUA of immunofluorescence signals for each marker in cytokeratin-positive cells from a breast cancer tissue microarray. Analysis of 177 breast cancer specimens revealed a strong positive correlation between p38γ and RhoC expression (Fig. 3H). Taken together with our in vitro results, these data strongly support a p38γ–RhoC relationship in breast cancer, one that likely involves p38γ regulation of RhoC expression.

p38γ affects the metastatic properties of other aggressive breast cancer cell lines

Because p38γ specifically alters the actomyosin contractile motility of MDA-MB-231 cells by affecting RhoC expression, we asked whether it plays a similar role in other mesenchymal-like breast cancer cell lines. To address this question, we used 2 additional widely studied breast cancer cell lines—Hs578t and BT549—both of which have increased levels of phosphorylated p38γ compared with both MCF-10A and HME nontumorigenic mammary epithelial cells (Fig. 4A). We transiently knocked down p38γ expression in these 2 cell lines with siRNA (Fig. 4B) and observed the effects on the actin cytoskeleton and cell motility.

siRNA knockdown of p38γ (sip38γ) dramatically affected the actin cytoskeletal architecture and cell shape of both cell lines in a manner consistent with 231 shp38γ cells (Fig. 4C and D) and reduced cell motility as measured by a bead motility assay in BT549 (E) and Hs578t (F) cells (for 2 BT549 siRNAs: *, P = 0.0428; **, P = 1.64 × 10⁻²; for 2 Hs578t siRNAs: *, P = 0.0001; **, P = 0.0012). G, RhoC expression is reduced in siRNA-transfected BT549 and Hs578t cells.
D): sip38γ cells moved significantly less than scrambled cells (Fig. 4E and F). p38γ knockdown in these cell lines also reduced RhoC expression (Fig. 4G). Taken together, these results support our conclusion that p38γ plays a crucial role in promoting motility of aggressive breast cancer cells by modulating RhoC expression.

**p38γ is associated with the basal-like breast cancer subtype**

Having discovered that p38γ is associated with mesenchymal-like cell motility and is overactivated in 3 basal-like breast cancer cell lines, we hypothesized that p38γ is associated with the basal-like breast cancer subtype. To test this hypothesis, we assayed p38γ expression in samples of 43 patients with breast cancer who were previously analyzed for molecular subtype by PAM50 (26). We divided the cohort into high (top 25%) and low (bottom 75%) p38γ-expressing tumors and examined the association between p38γ expression level and molecular subtype. We found that the basal-like subtype is significantly enriched in the high p38γ-expressing tumors ($P = 0.018$, Fig. 5A) whereas none of the other subtypes examined showed significant association with p38γ expression (data not shown). Taken together with our in vitro data, these clinical data strongly support an association between high p38γ expression and the basal-like breast cancer subtype.

**p38γ is necessary for breast cancer metastasis in vivo and is clinically associated with lower overall patient survival**

On the basis of our in vitro observations, we hypothesized that p38γ knockdown reduces the metastatic potential of MDA-MB-231 breast cancer cells in vivo. To test this hypothesis, we orthotopically xenografted athymic nude mice with 231 scrambled and shp38γ cells and allowed tumors to grow for 14 weeks, at which point we resected the tumors and analyzed the contralateral respective lymph node for signs of metastasis (see Supplementary Materials and Methods). Two thirds of mice injected with scrambled cells presented with...
lymphatic invasion and metastasis compared with 1 of 9 shp38y-injected mice (Fig. 5B and C). These in vivo data, combined with the extensive body of in vitro data presented here, strongly suggest that p38y is necessary for metastasis and that it exerts its effects, at least in part, by promoting cell motility through regulation of RhoC.

As a final determination of the clinical relevance of p38y expression, we assayed p38y levels in a cohort of 118 breast cancer cases containing patient survival data. Using the same high/low cutoff values as the molecular subtype analysis, we found a significant association between high p38y expression and lower overall patient survival (P = 0.013, Fig. 5D). These clinical data support our in vitro and in vivo findings that p38y is an important mediator of breast cancer cell aggressiveness, establishing that p38y expression has important implications for outcome of patients with breast cancer.

Discussion

Because the breast is a nonvital organ, primary tumor burden is very rarely the direct cause of cancer-specific mortality. Instead, metastasis of cells from the primary tumor to vital organs results in patient death. Here, we show that p38y is a novel metastasis-associated gene, which acts in part by affecting cytoskeletal orientation, cell motility, and RhoC.

The importance of the p38 MAPK pathway in cancer has been appreciated (6, 27), but diverse, and sometimes contradictory, roles have been described for p38 in cancer (13). In agreement with other recent findings (15, 28), we show that at least some of the discrepancy in p38 function may be attributed to the distinct contributions of p38 isoforms. The p38 MAPK pathway is ubiquitously used in stress response. It logically follows that metastasizing cancer cells, which encounter an ever-changing milieu of cellular stresses, may gain survival advantages under stressed conditions upon modulation of the appropriate p38 MAPK isoforms; thus, dissecting the contributions of each p38 isoform would allow more precise targeting of specific subsets of cancer. p38y is an especially promising drug target, as, in addition to the data presented here, it is a kinase, has restricted tissue expression (8, 10, 11), and lacks a phenotype when knocked out in mice (29)—possibly indicating that its inhibition may offer a differential detrimental effect on tumor versus normal cells.

Using a computational cell model in combination with live cell microscopy studies, we showed that p38y promotes breast cancer cell motility at least in part by mediating actin cytoskeletal remodeling to create proper stress fiber orientation. Using the computational cell models, we first noted that whereas the observed whole-cell locomotion could be produced by simultaneous action of all stress fibers in scrambled cells, the experimentally observed ineffective locomotion of shp38y cells was only possible if the action alternated between the 2 families of actin bundles seen in this cell phenotype—a result that would prove difficult to show by cell biologic techniques alone.

The computational model predicted, and subsequent biologic experiments verified, the presence of left-right leading edge protrusion oscillations in both scrambled and shp38y cells. We note that other groups have identified oscillations in components of the leading edge (30, 31); however, these oscillations all involved forward–backward (protrusion/retraction) movement of the leading edge as a whole. To the best of our knowledge, the data presented here are thus the first evidence of left-right oscillations in the leading edge. Interestingly, the principal difference between the 2 cell types studied here (scrambled and shp38y) lies in the periodicity of these oscillations. Through detailed in silico experimentation (Fig. 2, Supplementary Fig. S4), we determined that leading edge protrusion oscillation periodicity is influenced by and inseparable from cytoskeletal architecture. This inseparability sharpens the question of exactly how leading edge actin dynamics are linked to cell shape and cytoskeletal morphology. Although this is a subject for future investigation, we do speculate on the chain of events: p38y knockdown results in cytoskeletal architecture changes, which lead to alteration of cell shape, compensatory changes in leading edge protrusion periodicity, and ultimately modified whole-cell motility.

Oscillation of other components of cell motility, such as cell shape (32) and trailing edge retraction (33), has been shown to be essential for productive cell motion in Dicystostelium discoideum (32) and fish keratocytes (33). We expect further investigations to uncover links between these processes and leading edge protrusion oscillations.

p38y bears analogies with other mediators of normal mesenchymal differentiation such as twist and snail, which have also been shown to be important promoters of cancer progression (34, 35); p38y functions in muscle cell differentiation and thus it is consistent that it functions in mesenchymal-like breast cancer cells. Interestingly, p38y seems to exert its effects independently of classical cell differentiation markers, as p38y knockdown does not alter expression of epithelial-to-mesenchymal transition markers such as vimentin or E-cadherin (data not shown) despite significantly reverting the mesenchymal-like phenotype of aggressive breast cancer cells. Although many other genes have been shown to drive metastatic transition (36), based on the data presented here, we propose that p38y serves as a crucial regulator of the major cytoskeletal changes necessary for the switch to rapid, mesenchymal-like cell motility— independent of differentiation status—at least in part by modulating RhoC.

RhoC is involved in stress fiber formation and actomyosin contraction (37, 38)—both of which are perturbed by p38y knockdown—and has previously been linked to the p38 MAPK pathway (39). RhoC also drives metastasis in several types of cancer, including breast cancer (37, 40–42), and plays a larger role in stress fiber formation and contraction than RhoA (43); thus, we postulated that changes in RhoC expression influence the shp38y phenotype. Supporting this hypothesis, we found that reexpressing RhoC alone was sufficient to restore motility to shp38y cells—a surprising feat, given the multitude of proteins involved in cell motility (44, 45), which highlights the importance of RhoC in p38y-mediated cell motility. Further supporting the p38y–RhoC link is our finding that expression of the 2 proteins is concurrently altered in...
clinical breast cancer specimens (Fig. 5A), suggesting that the p38γ–RhoC axis may be functionally significant—and a potentially druggable target—in the clinic.

We discovered that p38γ regulates RhoC expression by preventing RhoC ubiquitination and subsequent lysosomal degradation. Although other p38 isoforms have been linked to protein ubiquitination (46, 47), ours is the first evidence of p38γ contributing to this process. Ubiquitination and protein degradation have recently emerged as important mechanisms for regulating Rho GTPase expression (48); however, this is the first demonstration of modulating RhoC ubiquitination as a relatively fast mechanism to regulate RhoC action within a time domain relevant to cell motion. Further research into the specific proteins and mechanisms regulating ubiquitination of RhoC and other Rho GTPases should have significant impact on our understanding of how cell motility and metastasis are regulated.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Sofia D. Merajver, one of the Senior Editors of Cancer Research, is a coauthor of this article. In keeping with the AACR’s Editorial Policy, the paper was peer reviewed and a member of the AACR’s Publications Committee rendered the decision concerning acceptability.

Acknowledgments

The authors thank the University of Michigan Microscopy and Image Analysis laboratory for excellent technical support with all microscopy work, Dr. J. Erby Wilkinson and the UM Pathology Core for tissue processing and pathologic analysis, and Dr. Dayfyl Thomas and the UMC Cell Core for carrying out the AQUA staining and image acquisition.

Grant Support

This work was supported by the Department of Defense Breast Cancer Research Program through a Predoctoral Traineeship award (BC083262; to D.T. Rosenthal) and a Multidisciplinary Postdoctoral award (A.C. Ventura), an NIH Cellular and Molecular Biology Training grant (T32-GM07315; D.T. Rosenthal), the Burroughs Wellcome Fund (S.D. Merajver), the Breast Cancer Research Foundation (S.D. Merajver), and a Department of Energy PECASE award (K. Garikipati). A.C. Ventura is a member of the Carrera del Investigador Cientifico (CONICET).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 14, 2011; revised July 22, 2011; accepted August 5, 2011; published OnlineFirst August 23, 2011.

References

26. Rosenthal ET, Dafydd Thomas and the UMCCC Tissue Core for pathologic analysis, and Dr. J. Erby Wilkinson and the UMCCC Tissue Core for carrying out the AQUA staining and image acquisition.

Cancer Res; 71(20) October 15, 2011

6348

Cancer Research
p38γ Promotes Breast Cancer Cell Motility and Metastasis through Regulation of RhoC GTPase, Cytoskeletal Architecture, and a Novel Leading Edge Behavior


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-1291

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/08/23/0008-5472.CAN-11-1291.DC1

Cited articles
This article cites 47 articles, 24 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/20/6338.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/71/20/6338.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.